



SAR

SARS-CoV-2

lgcstandards.com/AXIO

ISO/IEC 17043 | ISO/IEC 17025 | ISO 9001



0001

SAR

SARS-CoV-2

The SARS-CoV-2 Clinical Scheme (SAR) is the Proficiency Testing answer from AXIO to the Global COVID-19 pandemic.

Governments, health bodies, hospitals, virology labs and indeed most of the world's population find themselves locked in a war with the novel virus COVID-19. LGC is now directly involved in COVID-19-related work, from supporting diagnostic kit manufacturers, diagnostic testing and clinical research to providing quality assurance tools to ensure reliability of measurements being made.

As increasing numbers of diagnostic methods are made available in the global fight against COVID-19, it is essential that laboratories ensure that their application of methods and subsequent results are reliable and accurate using external quality assurance tools, including proficiency testing.

Test materials include swab and plasma samples, to meet all Clinical laboratories and Point of Care Testing requirements.

Test Material*	Analyte*
Liquid sample simulating nasopharyngeal swab	SARS-CoV-2 Antigen.
Plasma samples	SARS-CoV-2 Antibodies (IgA, IgG, IgM, Total Ab).
Liquid sample simulating nasopharyngeal swab	SARS-CoV-2 Molecular.
2 Swab based samples	SARS-CoV-2 Positive/Negative.

* The full range and availability of test materials and analytes is determined on an annual basis and may be added or removed. For accredited and non-accredited status please see current application form/scheme description.

